Table 1.
Relative increase in TFα levels after oral intake of B. ovatus D-6
| Sera samples | Increase in TFαR from pre-immunization TFαR | |||||
|---|---|---|---|---|---|---|
| Early | Late | Recovery | ||||
| IgM | IgG | IgM | IgG | IgM | IgG | |
| Group A (1010 bacteria/day) | ||||||
| A1 | + | – | ++ | – | + | – |
| A2 | – | – | +++ | +++ | + | + |
| A3 | +++ | +++ | +++ | +++ | +++ | +++ |
| A4 | + | – | + | + | – | – |
| A5 | +++ | – | +++ | + | +++ | +++ |
| A6 | +++ | – | +++ | ++ | – | +++ |
| Group B (109 bacteria/day) | ||||||
| B1 | + | – | + | + | ++ | + |
| B2 | +++ | – | ++ | – | ++ | – |
| B3 | – | – | + | + | + | + |
| B4 | – | – | – | – | – | – |
| B5 | +++ | – | +++ | – | +++ | – |
| B6 | ++ | – | – | – | – | – |
| Group C (108 bacteria/day) | ||||||
| C1 | – | – | – | – | – | – |
| C2 | – | – | – | – | – | – |
| C3 | – | – | – | – | – | – |
| C4 | +++ | +++ | +++ | +++ | +++ | ++ |
| C5 | ++ | – | + | – | – | – |
| Group D (107 bacteria/day) | ||||||
| D1 | – | – | – | – | – | – |
| D2 | – | – | – | – | – | – |
| D3 | – | – | ++ | – | – | – |
| D4 | + | – | + | +++ | – | ++ |
| D5 | – | – | – | – | – | – |
| Group E (106 bacteria/day) | ||||||
| E1 | – | – | – | – | – | – |
| E2 | + | – | +++ | + | – | ++ |
| E3 | – | – | – | – | – | – |
| E4 | – | – | + | – | + | – |
| E5 | – | – | – | – | – | – |
Serum samples were taken before (day -1), 14 or 21 days after first intake (early point), 49 or 56 days after first intake (late point), and beyond 77 days (recovery; 3 weeks after the last intake). Serum samples were analyzed by ELISA for IgM and IgG antibody binding to PAA-TFα and PAA-Lec. The relative TFα level (TFαR) was calculated, and the percent change relative to the pre-immunization TFαR value was determined for each time point. An increase between 15 and 50 % was designated as (+), between 51 and 100 % as (++), and over 100 % as (+++). Percent values lower than 15 % were considered negative (−)